Fosun Pharma's CAR-T Therapy Receives IND Approval; Hansoh Pharma Files for Hong Kong IPO

Monday | How to Dispose of 2 Million Tons of Medical Waste Annually: Can “Internet + Medical Waste” Master the Market and Achieve a 100% Disposal Rate?

Transparency Market Research (TMR)’s latest report shows that the global medical waste management market exceeded $10 billion in 2016. Based on a compound annual growth rate (CAGR) of 5.1%, the market size is projected to surpass $22.3 billion by 2025. This sector holds significant potential.

Tuesday | Hundreds of Millions in Two Years: Internet + Primary Care Medical Laboratory Testing Has Become an Investment Hotspot [Special Report on Internet-Based Primary Care Medical Laboratory Testing]

Tian Min believes that so-called to-C enterprises, from the perspective of customer acquisition, still need to maintain close ties with large hospitals and establish patient referral mechanisms to ensure the effective operation of these centers. From this standpoint, they are essentially to-B businesses, centered on how to channel patient flow from large hospitals into their own institutions, which constitutes a significant core competitive advantage.

Wednesday | Exclusive Insight: Lin Feng, Founder of Bode Jialian, on Raising ¥1 Billion in One Year and Building the “Airport” Model for Physician Groups

In Lin Feng’s vision, the goal is to build an ecosystem for physician groups and a broader healthcare ecosystem. Adopting the “carrier strike group” model, the strategy begins with establishing smaller vessels such as “supply ships” and “destroyers,” each specializing in different medical disciplines. Ultimately, an “aircraft carrier” will be developed as a premier, highly sophisticated integrated entity, enabling physicians and their teams within the physician groups to implement on-the-ground operations and facilitate personnel mobility.

Thursday | Neusoft’s Total Revenue Exceeds 570 Million, Maidi’s Gross Margin Surpasses 80%: Behind the Semi-Annual Report Data of Medical IT Companies...

In August, listed companies involved in the medical IT business successively released their 2018 semi-annual reports. Based on a comprehensive analysis of these interim reports, VCBeat has drawn the following conclusions:

1. Reducing the cost of outsourced products and strengthening the sales of high-gross-margin IT solutions in anesthesia, critical care, and operations & maintenance services can significantly improve the gross profit margin of healthcare IT companies;

2. With policy support, IT companies across the industry, such as Donghua and Yanhua, are increasing their market focus on the healthcare sector;

3. Cloud-based next-generation hospital business systems, healthcare payment solutions, and artificial intelligence are the primary areas of innovation for medical IT companies today.

Friday | Why Has Zhejiang’s Health Industry Soared? Elites Discuss Trends at the Health Expo

Xu Runlong, Deputy Director of the Zhejiang Provincial Health and Family Planning Commission, stated that the health industry is becoming a new function, new advantage, and new driving force for Zhejiang’s economic development. The Zhejiang International Health Industry Expo serves as an important exhibition platform in the province that integrates internationalization, professionalism, market orientation, and public engagement; it also acts as a barometer and brand pinnacle for the development of Zhejiang’s health industry. Since 2015, the expo has attracted participants and exhibitors from nearly 30 countries, regions, and international organizations, more than 700 renowned domestic and foreign enterprises and institutions, and 37,000 business attendees.

Eisai’s Blockbuster New Liver Cancer Drug “Lenvatinib” Approved for Launch in China

On September 4, the approval status of Eisai’s marketing application (JXHS1700042) for lenvatinib, a multi-target kinase inhibitor (VEGFR1-3, FGFR1-4, PDGFRα, KIT, RET), was updated to “Approval Completed – Pending Certificate Issuance.” Verified by PharmaCube, the product has been officially approved for marketing by the National Medical Products Administration.

Hansoh Pharma’s Hong Kong IPO

On September 6, Hansoh Pharmaceutical filed an IPO application with the Hong Kong Stock Exchange (HKEX). The entity going public in Hong Kong is Hansoh Pharma, with Morgan Stanley and Citigroup serving as joint sponsors. The reason this news may have escaped the attention of most observers likely lies in the name used for the HKEX filing. As disclosed in the announcement, the company’s name for its Hong Kong IPO is “Hansoh Pharma,” the English transliteration of “Hansoh.”

Ping An Good Doctor and China Resources Sanjiu Forge Strategic Partnership, Further Advancing Their New Retail Pharmaceutical Layout

On September 7, Ping An Good Doctor (01833.HK), China’s leading one-stop healthcare ecosystem platform, entered into a strategic cooperation agreement with China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. The two parties will integrate their respective advantageous resources, leveraging Ping An Good Doctor’s leading AI-driven medical technology and extensive user base, combined with China Resources Sanjiu’s product strengths in the OTC and prescription drug sectors, to jointly build a new “Internet + Healthcare” business model. This collaboration aims to enhance the medical service capabilities of both parties while promoting the deep integration of mobile internet and the healthcare industry.

First In Vivo Gene Editing Therapy Releases Initial Data

On September 6, US biotechnology company Sangamo announced early data from its in vivo gene-editing therapy SB-913 for Hunter syndrome (also known as MPS II). Two patients receiving low doses showed no response, but two patients receiving medium doses exhibited significant reductions in glycosaminoglycan (GAG) levels after 16 weeks of treatment with SB-913 (urinary GAGs decreased by 51%, dermatan sulfate by 32%, and heparan sulfate by 61%). However, the enzyme expressed by the gene (IDS) was not detected in peripheral blood. Sangamo stated that the reduction in GAGs is sufficient to indicate repair of the IDS gene; the non-detection of IDS may be attributed to insufficient sensitivity of current detection methods or to the possibility that IDS was synthesized but rapidly taken up by target tissues.

Tianmai Biotech Partners with GE Healthcare to Build a World-Leading Production Line

On September 6, Zhuhai Trinomab Biotechnology Co., Ltd. (Trinomab) announced a collaboration with GE Healthcare to establish a world-class FlexFactory™ production line at the Zhuhai International Health Port. The platform is expected to be delivered and operational by 2020. The facility will include equipment for a 200L pilot-scale production line and a 1000L commercial-scale production line, enabling seamless switching between the two lines in the future. Additionally, GE Healthcare’s Fast Trak China team will provide Trinomab with comprehensive technical bridge services.

A Major Leap in Import Substitution! Chinese-Made Medical Devices Top a World-Renowned Authoritative Journal

On September 4 (evening of September 3, 2018, UK time), The Lancet, a world-leading authoritative medical journal, published in full the results of the TARGET AC trial, a large-scale European clinical study on the Firehawk sirolimus-targeted eluting stent system (hereinafter referred to as the Firehawk stent), an independently developed Chinese product. The journal stated that this study had resolved a major challenge that had plagued the field of cardiovascular intervention worldwide for more than a decade.

What has galvanized China’s medical device industry is that, for the first time in its nearly 200-year history since its founding, The Lancet has published clinical study results on a Chinese medical device product. This marks the Firehawk stent, independently developed and manufactured by a Chinese enterprise, as a leader setting new global standards for the next generation of coronary stents.

China’s First Third-Party Medical Laboratory Performance Evaluation Report Released

On September 5, the Health Development Research Center of the National Health and Family Planning Commission released in Guangzhou the first report on the evaluation of effectiveness and summary of experiences of third-party medical laboratories in mainland China. The report indicates that the third-party medical testing industry is developing rapidly, with its scale expected to reach nearly RMB 30 billion within the next two years.

The Yangtze River Delta Pediatric Medical Alliance Is Officially Established

On September 1, the Yangtze River Delta Pediatric Medical Alliance was established to accelerate the enhancement of pediatric medical services in the Yangtze River Delta region and achieve effective supply and homogeneous development of regional healthcare services. Spearheaded by Shanghai Children’s Hospital, Nanjing Children’s Hospital, the Children’s Hospital of Zhejiang University School of Medicine, and Anhui Provincial Children’s Hospital, the alliance has already attracted 81 member institutions. In the future, patients seeking care at these institutions are expected to benefit from integrated medical services.

This week, there were a total of 26 financing events in the medical field both domestically and internationally.

Advancements and innovations in life sciences have brought a series of breakthrough solutions to human health and the treatment of various diseases: the emergence of gene sequencing has transformed our understanding of diseases, while tumor immunotherapy and minimally invasive techniques have provided novel therapeutic approaches. Looking ahead, beyond the continued development of these technologies, artificial intelligence, cell therapy, and precision gene therapy are all poised to bring disruptive revolutions to the industry. “Innovation in the pharmaceutical industry is more disruptive than innovation in the internet sector.” (Source: Health Point)

On September 6, Mirror, a fitness platform company based in New York, announced the launch of its consumer-oriented home virtual fitness product. The device features an LCD panel for streaming videos and music, connects to wearable heart-rate monitors, and uses a built-in camera to provide users with real-time feedback on their workouts. When not in use, it functions as a full-length mirror. The product is priced at $1,495.

In addition, Mirror announced that it had secured $25 million in funding from Spark Capital. Earlier this February, Mirror completed its $13 million Series A financing round, also led by Spark Capital, with other participants including Lerer Hippeau, First Round Capital, and Primary Venture Partners.

Source: https://www.mobihealthnews.com

On September 5, Headspace, a developer of meditation apps, announced the acquisition of Alpine.Ai, an AI system with voice capabilities, planning to leverage its digital assistant platform to enhance user engagement. This acquisition will further advance Headspace’s development in conversational products.

Alpine.AI will significantly enhance Headspace’s voice platform, enabling users to engage in more natural conversations with the meditation app through voice assistants such as Google Home or Alexa. Alpine.AI has already built a platform for creating conversational applications that is highly compatible with Headspace’s existing features.

Source: https://www.mobihealthnews.com

This report begins with the technological foundations of CAR-T therapy to analyze the current status and prospects of its industry development. It places particular emphasis on the structure and characteristics of the industrial chain extending from CAR-T therapy. Given that CAR-T technology has emerged only recently and its industrialization is in its early stages, the report will also focus on the current R&D landscape, as well as the core competitive factors for companies at different future development stages. Furthermore, the financing and investment characteristics and opportunities within the CAR-T therapy sector fall within the scope of this study.

The report shows that the GMV growth rate of niche brands reached 96%, with a purchase rate 1.5 times the industry average, while sales of aesthetically appealing toothpastes surged by 98-fold. Novel products such as pump-action toothpaste and teeth-whitening devices saw explosive growth of 258% and 133% respectively, gaining strong consumer traction. Data on the proportion of consumers purchasing from different brands over the past three years indicates a gradual increase in the number of individuals buying two or more toothpaste brands within a year. Evidently, consumers are more willing to try new brands, creating greater market opportunities for niche players.